Indivior (INDV) CLO awarded RSUs and 104,300 performance units

Rhea-AI Filing Summary

Indivior Pharmaceuticals’ Chief Legal Officer Jeffrey W. Burris reported new equity awards. He acquired 26,897 shares of common stock on February 10, 2026 through a grant of restricted stock units with a stated value of $0 per share, bringing his direct holdings to 27,657 common shares.

He was also granted 104,300 performance stock units on February 9, 2026. These units relate to a conditional award originally granted on March 3, 2023, for 104,300 shares, with performance conditions certified on February 9, 2026 and vesting on March 3, 2026, subject to continued employment. The new RSUs vest in three equal annual installments beginning February 10, 2027.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Burris Jeffrey W

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	26,897	$0.00	--
Grant/Award	Performance Stock Units	104,300	$0.00	--

Holdings After Transaction: Common Stock — 27,657 shares (Direct); Performance Stock Units — 104,300 shares (Direct)

Footnotes (1)

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer. On March 3, 2023, the Reporting Person was granted a conditional award for 104,300 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burris Jeffrey W

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		26,897(1)	A	$0	27,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	$0	02/09/2026		A		104,300		03/03/2026(2)	(2)	Common Stock	104,300	$0	104,300	D

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.

2. On March 3, 2023, the Reporting Person was granted a conditional award for 104,300 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026.

Remarks:

Exhibit 24 Power of Attorney

	/s/Alice Givens, Power of Attorney	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Indivior (INDV) report for Jeffrey W. Burris?

Indivior reported that Chief Legal Officer Jeffrey W. Burris acquired 26,897 shares of common stock via a grant with a stated price of $0. He also received 104,300 performance stock units, both held directly, as part of his equity-based compensation.

How many Indivior (INDV) common shares does Jeffrey W. Burris now hold?

After the reported grant, Jeffrey W. Burris beneficially owns 27,657 Indivior common shares directly. This figure reflects the 26,897-share award reported in the filing, added to his prior holdings, and represents his post-transaction non-derivative ownership position.

What restricted stock units were granted to Indivior (INDV) CLO Jeffrey W. Burris?

Burris received a grant of restricted stock units representing 26,897 Indivior common shares at a stated price of $0. Each unit converts into one share and vests in three equal annual installments starting February 10, 2027, conditional on his continued service.

What are the terms of Jeffrey W. Burris’s 104,300 Indivior (INDV) performance stock units?

The 104,300 performance stock units stem from a conditional award granted March 3, 2023. Performance conditions were certified on February 9, 2026, and the award is scheduled to vest on March 3, 2026, subject to Burris’s continued employment with Indivior.

Are Jeffrey W. Burris’s Indivior (INDV) equity awards held directly or indirectly?

Both the 26,897-share restricted stock grant and the 104,300 performance stock units are reported as held directly by Jeffrey W. Burris. The filing lists his ownership form as “D” (direct) for the non-derivative shares and derivative units.

When do Jeffrey W. Burris’s Indivior (INDV) restricted stock units begin vesting?

The restricted stock units granted to Burris begin vesting on February 10, 2027. Vesting occurs in three equal annual installments starting on that date, provided he continues to serve the company throughout each vesting period, according to the filing’s footnote.